Tirzepatide's timeline has three chapters in the published trials: the climb to your dose, the long stretch toward a 72-week result, and what happens if the drug stops. Each chapter has its own trial.
| Measure | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Mean weight change | −3.1% | −15.0% | −19.5% | −20.9% |
| Lost 5% or more | 35% | 85% | 89% | 91% |
| Lost 10% or more (label) | 18.8% | 68.5% | 78.1% | 83.5% |
| Lost 15% or more (label) | 8.8% | 48.0% | 66.6% | 70.6% |
| Lost 20% or more | 3% | not in abstract | 50% | 57% |
The 5% row comes from the NEJM abstract, rounded; the 10% and 15% rows come from the Zepbound label's Study 1 table, which is the same trial (NCT04184622). The 20.9% figure for 15 mg is the treatment-regimen estimand. You may see 22.5% quoted elsewhere; that is the efficacy estimand, which counts only people who stayed on treatment, and it should be labeled that way.
Who was in SURMOUNT-1?
The trial assigned 2,539 adults with a BMI of 30 or more, or 27 or more with at least one weight-related complication, to 5 mg, 10 mg or 15 mg of tirzepatide or placebo in equal groups, once weekly for 72 weeks. People with diabetes were excluded. At baseline, the average participant weighed 104.8 kg with a BMI of 38.0, and 94.5% had a BMI of 30 or higher.
That matters for reading the results. A 20.9% mean loss from about 105 kg is roughly 22 kg; the same percentage from a lower starting weight is fewer kilograms. That is arithmetic, not a prediction.
Chapter 1: the escalation months
SURMOUNT-1 built in a 20-week escalation period. On the label schedule, you start at 2.5 mg, add 2.5 mg no sooner than every 4 weeks, and can reach 15 mg at week 21 at the earliest. People assigned to 5 mg got there in four weeks; the 15 mg group spent five months climbing.
So a week-12 snapshot on 15 mg is really a snapshot on 7.5 mg. The labeled dose ladder is in our tirzepatide dosage chart.
Chapter 2: the 36-week checkpoint
SURMOUNT-4 (JAMA, 2024) gives a useful midpoint. Its 783 participants all took their maximum tolerated dose, 10 mg or 15 mg, for a 36-week open-label lead-in. The 670 who completed it had lost a mean 20.9% by week 36.
That number is not directly comparable with SURMOUNT-1's 72-week result: it counts only people who finished the lead-in, which tends to raise the average. Treat it as "what people who tolerated a high dose for nine months looked like", not as a typical 36-week outcome.
Chapter 3: stopping versus continuing
SURMOUNT-4 then randomized those 670 people to keep taking tirzepatide or switch to placebo for 52 more weeks.
| Outcome | Continued tirzepatide | Switched to placebo |
|---|---|---|
| Weight change, week 36 to 88 | −5.5% | +14.0% |
| Kept at least 80% of lead-in loss at week 88 | 89.5% | 16.6% |
| Total change, week 0 to 88 | −25.3% | −9.9% |
The authors' conclusion was direct: withdrawing tirzepatide led to substantial regain, while continuing maintained and added to the loss. The placebo group still ended below its starting weight on average, but most of the advantage was gone within a year.
For budgeting, that means the realistic comparison is the cost of years, not months. Our tirzepatide cost guide runs 12-month figures.
How does tirzepatide compare with semaglutide over 72 weeks?
SURMOUNT-5 (NEJM, 2025) is the head-to-head trial. In 751 adults with obesity and no type 2 diabetes, randomized to the maximum tolerated dose of each drug for 72 weeks, mean weight change was −20.2% with tirzepatide (10 or 15 mg) and −13.7% with semaglutide (1.7 or 2.4 mg). Waist circumference fell 18.4 cm versus 13.0 cm.
Two cautions. The trial was open-label, so participants knew which drug they took. And it was funded by Lilly, which makes tirzepatide. The full comparison is on our semaglutide vs tirzepatide page.
Why do the dose groups end so far apart?
SURMOUNT-1 shows a clear dose response: 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg. The step from 5 mg to 10 mg added far more than the step from 10 mg to 15 mg. Side-effect dropouts moved the other way: adverse events led 4.3%, 7.1% and 6.2% of people on 5, 10 and 15 mg to stop, against 2.6% on placebo.
The share reaching 20% or more tells the same story from another angle, 50% at 10 mg and 57% at 15 mg against 3% on placebo. The trial did not test switching doses mid-course, so it cannot tell you whether moving from 10 mg to 15 mg would add weight loss for you. That is a decision for you and your prescriber, weighing tolerance against benefit.
What these numbers cannot tell you
- Your dose. The 5 mg and 15 mg results differ by almost 6 percentage points. Not everyone reaches 15 mg, and the label lists 5 mg and 10 mg as maintenance doses too.
- Compounded versions. All three trials used branded tirzepatide. Compounded tirzepatide is not FDA-approved, is made with the drug in Zepbound but is not the same product, and has no published trial results.
- Diabetes. SURMOUNT-1 excluded people with diabetes, so its results are not a benchmark if you have type 2 diabetes.
Finally, the trials measured weight at set visits and reported averages. Your own record, a monthly weigh-in alongside your dose and any side effects, is what your prescriber needs to judge whether a dose is working. The detailed trial designs are on our SURMOUNT trial results page.
Frequently asked questions
How much weight do people lose on tirzepatide 5 mg?
In SURMOUNT-1, the 5 mg group lost a mean 15.0% of body weight at 72 weeks under the treatment-regimen estimand, against 3.1% on placebo. About 85% lost at least 5%, and 48.0% lost at least 15% per the Zepbound label's Study 1 table. Those participants had no diabetes.
Is the 22.5% tirzepatide figure accurate?
It is a real SURMOUNT-1 result, but it is the efficacy estimand, which reflects people who stayed on 15 mg as assigned. The treatment-regimen estimand, which counts everyone regardless of stopping, gives 20.9% for 15 mg. When a site quotes 22.5% without saying which estimand it used, it is choosing the higher number without telling you.
What happens when you stop tirzepatide?
In SURMOUNT-4, people who switched to placebo after 36 weeks on tirzepatide regained a mean 14.0% of body weight over the next 52 weeks, while those who continued lost a further 5.5%. Only 16.6% of the placebo group kept at least 80% of their earlier loss, compared with 89.5% who stayed on tirzepatide.
How long until tirzepatide reaches full effect?
The trials measured the main result at 72 weeks, after a 20-week escalation period in SURMOUNT-1. Weight was still falling in people who continued treatment in SURMOUNT-4 between weeks 36 and 88. The trials do not define a single "full effect" date, and individual curves differ.
Did tirzepatide beat semaglutide in SURMOUNT-5?
On its primary endpoint, yes. Mean weight change at 72 weeks was −20.2% with tirzepatide versus −13.7% with semaglutide, each at the maximum tolerated dose, in 751 adults without type 2 diabetes. The trial was open-label and Lilly-funded, and both groups mostly had mild-to-moderate gastrointestinal side effects during escalation.
Sources
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022 — abstract read 2026-11-08 (PubMed record); doi 10.1056/NEJMoa2206038
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA 2024 — abstract read 2026-11-08 (PubMed record); doi 10.1001/jama.2023.24945
- Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med 2025;393:26-36 — abstract read 2026-11-08 (PubMed record)
- FDA label via DailyMed: Zepbound (tirzepatide) prescribing information — revised 8/2026; Study 1 responder table and dosing read 2026-11-08